Global Information
회사소개 | 문의

세계의 척수성 근위축증(SMA) 시장 예측 : Spinraza(스핀라자), AVXS-101, CK2127107, RG7916, Olesoxime, LMI070

Spinal Muscular Atrophy Market Global Forecast by Countries (USA, UK, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)

리서치사 Renub Research
발행일 2018년 11월 상품 코드 747133
페이지 정보 영문 121 Pages
가격
US $ 2,190 ₩ 2,486,500 Unprintable PDF by E-mail (Single User License)
US $ 2,690 ₩ 3,054,200 PDF by E-mail (5 User License)
US $ 2,690 ₩ 3,054,200 Unprintable PDF and Hard Copy
US $ 3,190 ₩ 3,621,900 PDF by E-mail (Global Site License)

주의 : 본 보고서는 PDF 파일 이용 시 라이선스에 따라 보고서 인쇄가 제한됩니다.
Single User License 구입 시에는 인쇄가 불가능하므로 이용에 주의하시기 바랍니다.



세계의 척수성 근위축증(SMA) 시장 예측 : Spinraza(스핀라자), AVXS-101, CK2127107, RG7916, Olesoxime, LMI070 Spinal Muscular Atrophy Market Global Forecast by Countries (USA, UK, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)
발행일 : 2018년 11월 페이지 정보 : 영문 121 Pages

세계의 척수성 근위축증(SMA : Spinal Muscular Atrophy) 시장에 대해 조사했으며, 현재 세계 시장 규모와 예측, 세계 및 국가별 시장·환자수·치료 환자 점유율 현황과 예측, 치료제 매출, 임상 연구·약제 파이프라인, 성장 촉진요인과 과제, 주요 기업 개요 등의 정보를 전해드립니다.

제1장 서론

제2장 분석 방법

제3장 주요 요약

제4장 세계의 척수성 근위축증(SMA) 시장 및 환자 분석

  • 시장
  • 환자수
  • 치료 환자수

제5장 점유율 분석 : 세계의 척수성 근위축증(SMA) 시장

  • 각국 시장 점유율
  • 환자 인구 점유율
  • 치료 환자 점유율

제6장 미국

  • 시장
  • 환자수
  • 치료 환자수

제7장 영국

제8장 독일

제9장 이탈리아

제10장 프랑스

제11장 스페인

제12장 일본

제13장 치료제 매출 : 척수성 근위축증(SMA)

  • Spinraza(스핀라자)
  • AVXS-101
  • CK2127107
  • RG7916
  • Olesoxime
  • LMI070

제14장 연구 상황 분석 : 척수성 근위축증(SMA)

  • 임상 연구
  • Drug Discovery 파이프라인

제15장 성장 촉진요인

  • R&D 자금 증가
  • Biogen의 액세스 프로그램

제16장 과제

  • 고액의 치료비
  • 일반적인 부작용

제17장 Biogen Inc.

  • 사업 개요
  • 계획/전략
  • 재무 분석

제18장 Novartis AG

제19장 Roche Holding AG

제20장 Cytokinetics, Inc.

KSM 18.11.30

List of Figures

  • Figure 2-1: Global - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
  • Figure 2-2: Global - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
  • Figure 2-3: Global - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
  • Figure 3-1: Global - Current & Forecast for Spinal Muscular Atrophy Market Share (Percent), 2017 - 2026
  • Figure 3-2: Global - Current & Forecast for Spinal Muscular Atrophy Patient Population Share (Percent), 2017 - 2026
  • Figure 3-3: Global - Current & Forecast for Spinal Muscular Atrophy Treated Patients Share (Percent), 2017 - 2026
  • Figure 4-1: United States - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
  • Figure 4-2: United States - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
  • Figure 4-3: United States - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
  • Figure 5-1: United Kingdom - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
  • Figure 5-2: United Kingdom - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
  • Figure 5-3: United Kingdom - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
  • Figure 6-1: Germany - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
  • Figure 6-2: Germany - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
  • Figure 6-3: Germany - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
  • Figure 7-1: Italy - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
  • Figure 7-2: Italy - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
  • Figure 7-3: Italy - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
  • Figure 8-1: France - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
  • Figure 8-2: France - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
  • Figure 8-3: France - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
  • Figure 9-1: Spain - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
  • Figure 9-2: Spain - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
  • Figure 9-3: Spain - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
  • Figure 10-1: Japan - Current & Forecast for Spinal Muscular Atrophy Market (Million US$), 2017 - 2026
  • Figure 10-2: Japan - Current & Forecast for Spinal Muscular Atrophy Patients (Number), 2017 - 2026
  • Figure 10-3: Japan - Current & Forecast for Spinal Muscular Atrophy Treated Patients (Number), 2017 - 2026
  • Figure 11-1: Global - Current & Forecast for Spinraza Sales (Million US$), 2017 - 2026
  • Figure 11-2: Global - Current & Forecast for AVXS-101 Sales (Million US$), 2017 - 2026
  • Figure 11-3: Global - Current & Forecast for CK212710 Sales (Million US$), 2022 - 2026
  • Figure 11-4: Global - Current & Forecast for RG7916 Sales (Million US$), 2024 - 2026
  • Figure 11-5: Global - Current & Forecast for LMI070 Sales (Million US$), 2021 - 2026
  • Figure 12-1: Spinal Muscular Atrophy Drugs Development Pipeline, September 2018
  • Figure 15-1: Biogen - Global Sales (Million US$), 2013 - 2017
  • Figure 15-2: Biogen - Forecast for Global Sales (Million US$), 2018 - 2026
  • Figure 16-1: Novartis - Global Sales (Million US$), 2013 - 2017
  • Figure 16-2: Novartis - Forecast for Global Sales (Million US$), 2018 - 2026
  • Figure 17-1: Roche - Global Sales (Million US$), 2013 - 2017
  • Figure 17-2: Roche - Forecast for Global Sales (Million US$), 2018 - 2026
  • Figure 18-1: Cytokinetics - Global Sales (Thousand US$), 2013 - 2017

List of Tables

Table 12 1: Global - Spinal Muscular Atrophy Clinical Study Status, 2018

Title:
Spinal Muscular Atrophy Market Global Forecast by Countries (United States, United Kingdom, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc).

Spinal muscular atrophy is a disease that causes muscle weakness which mostly appears in newborn children. Spinal muscular atrophy disease incidence of approximately 1 in 10,000 newborns and a prevalence of approximately 1 to 2 per 100,000 persons, globally. Spinal muscular atrophy is basically 4 types - Type 1, Type 2, Type 3 and type 4. Most patients suffers with Spinal muscular atrophy type 1. According to Renub Research Global Spinal Muscular Atrophy (SMA) market is anticipated to grow at a CAGR of 14.29 percent in future. This double digit growth rate will happen due to expected launch of new drugs, better reimbursement options and decline in drugs prices.

Spinal Muscular Atrophy (SMA) type 1 develop in less than 6 months of new born children in which patients are not in position to sit in their lifetime and normally they die within 6 months. In spinal muscular atrophy type 2, patients can sit but cannot walk. Type 2 is developed between 6-18 months of the new born children. Spinal muscular atrophy Type 3 patients can sit and walk and it developed when children age is less than 18 months. Spinal muscular atrophy Type 4 can develop during the adulthood.

Renub Research report titled "Spinal Muscular Atrophy Market Global Forecast by Countries (United States, United Kingdom, France, Germany, Spain, Italy & Japan), Drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070), Companies (Biogen Inc., Roche AG, Novartis AG, Cytokinetics Inc)" studies the global spinal muscular atrophy market and provides an all-encompassing analysis of the key growth drivers and challenges, market trends, key players and their projections for the future.

Spinal Muscular Atrophy Market New Drugs are expected to launch in recent years

At present only Biogen's Spinraza is approved for the treatment of spinal muscular atrophy patients in the various parts of the globe such as United States, Europe, and Japan etc. Other companies are also working for new drugs development and they hope to enter in the market place very soon as their drugs are in Phase III clinical trials.

By Country - Market Segmentation

Spinal muscular atrophy market by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is a leading market place due to increasing number of treated Patients, favorable reimbursement policies and increase in healthcare expenditure.

By Total & Treated Patients - Population Segmentation

Spinal muscular atrophy Total & Treated Patients by country has been segmented into United States, United Kingdom, France, Germany, Spain, Italy and Japan. United States is dominating in the treated SMA patients globally.

By Drugs - Market Segmentation

The report by Renub Research studies the spinal muscular atrophy six drugs (Spinraza, AVXS-101, CK2127107, RG7916, Olesoxime & LMI070) details with present and estimated global sales.

The Report has been analyzed from 9 Major Viewpoints:

  • 1. Global Spinal Muscular Atrophy Market (Present & Forecast)
  • 2. Global Spinal Muscular Atrophy Market Share, Patients Share, Treated Patients Share (Present & Forecast)
  • 3. Country Spinal Muscular Atrophy Market (Present & Forecast)
  • 4. Country Spinal Muscular Atrophy Patients Population (Present & Forecast)
  • 5. Country Spinal Muscular Atrophy Treated Patients Population (Present & Forecast)
  • 6. Spinal Muscular Atrophy Drugs Sales (Present & Forecast)
  • 7. Global - Clinical Study on Spinal Muscular Atrophy & Drugs Pipeline
  • 8. Growth Drivers and Challenges
  • 9. Key Spinal Muscular Atrophy Companies Initiatives and Financial Insight

Country Covered in this Report:

  • United States
  • United Kingdom
  • France
  • Germany
  • Italy
  • Spain
  • Japan

Drugs Details Covered in this Report:

  • Spinraza
  • AVXS-101
  • CK2127107
  • RG7916
  • Olesoxime
  • LMI070

Company Covered in this Report:

  • Biogen Inc.
  • Roche AG
  • Novartis AG
  • Cytokinetics Inc

Table of Contents

1. Introduction

  • 1.1. Market Definition
  • 1.2. Currency Conversion

2. Research Methodology

3. Executive Summary

4. Global Spinal Muscular Atrophy Market and Patients Analysis

  • 4.1. Spinal Muscular Atrophy Market
  • 4.2. Spinal Muscular Atrophy Patient Numbers
  • 4.3. Spinal Muscular Atrophy Treated Patient Number

5. Share Analysis - Global Spinal Muscular Atrophy

  • 5.1. Country Market Share
  • 5.2. Patients Population Share
  • 5.3. Treated Patients Share

6. United States

  • 6.1. Spinal Muscular Atrophy Market
  • 6.2. Spinal Muscular Atrophy Patient Numbers
  • 6.3. Spinal Muscular Atrophy Treated Patients

7. United Kingdom

  • 7.1. Spinal Muscular Atrophy Market
  • 7.2. Spinal Muscular Atrophy Patient Numbers
  • 7.3. Spinal Muscular Atrophy Treated Patient Numbers

8. Germany

  • 8.1. Spinal Muscular Atrophy Market
  • 8.2. Spinal Muscular Atrophy Patient Numbers
  • 8.3. Spinal Muscular Atrophy Treated Patients

9. Italy - Spinal Muscular Atrophy

  • 9.1. Spinal Muscular Atrophy Market
  • 9.2. Spinal Muscular Atrophy Patient Numbers
  • 9.3. Spinal Muscular Atrophy Treated Patient Numbers

10. France - Spinal Muscular Atrophy

  • 10.1. Spinal Muscular Atrophy Market
  • 10.2. Spinal Muscular Atrophy Patient Numbers
  • 10.3. Spinal Muscular Atrophy Treated Patient Numbers

11. Spain

  • 11.1. Spinal Muscular Atrophy Market
  • 11.2. Spinal Muscular Atrophy Patient Numbers
  • 11.3. Spinal Muscular Atrophy Treated Patient Numbers

12. Japan

  • 12.1. Spinal Muscular Atrophy Market
  • 12.2. Spinal Muscular Atrophy Patients
  • 12.3. Spinal Muscular Atrophy Treated Patient Numbers

13. Drugs Sales - Spinal Muscular Atrophy

  • 13.1. Spinraza
  • 13.2. AVXS-101
  • 13.3. CK2127107
  • 13.4. RG7916
  • 13.5. Olesoxime
  • 13.6. LMI070

14. Spinal Muscular Atrophy Study Status Analysis

  • 14.1. Spinal Muscular Atrophy Clinical Study
  • 14.2. Spinal Muscular Atrophy Drugs Development Pipeline

15. Growth Drivers

  • 15.1. Increasing Funding for Research & Development
  • 15.2. Biogen Access Programs

16. Challenges

  • 16.1. High Treatment Cost
  • 16.2. Common Side Effects

17. Biogen Inc.

  • 17.1. Business Overview
  • 17.2. Initiatives/Strategies
    • 17.2.1. Point 1
    • 17.2.2. Point 2
    • 17.2.3. Point 3
  • 17.3. Financial Insight

18. Novartis AG

  • 18.1. Business Overview
  • 18.2. Initiatives/Strategies
    • 18.2.1. Point 1
    • 18.2.2. Point 2
  • 18.3. Financial Insight

19. Roche Holding AG

  • 19.1. Business Overview
  • 19.2. Initiatives/Strategies
    • 19.2.1. Point 1
    • 19.2.2. Point 2
  • 19.3. Financial Insight

20. Cytokinetics, Inc.

  • 20.1. Business Overview
  • 20.2. Initiatives/Strategies
    • 20.2.1. Point 1
    • 20.2.2. Point 2
  • 20.3. Financial Insight
Back to Top
전화 문의
이용안내
 
BCC Research